GVHDS
MCID: GRF003
MIFTS: 71

Graft-Versus-Host Disease (GVHDS)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graft-Versus-Host Disease

MalaCards integrated aliases for Graft-Versus-Host Disease:

Name: Graft-Versus-Host Disease 57 37 55 38
Graft-Versus-Host Disease, Susceptibility to 57 29 40
Graft Versus Host Disease 75 59 55
Graft-Versus-Host Disease, Protection Against 57 13
Graft-Vs-Host Disease 72
Gvhds 57
Gvh 59

Characteristics:

Orphanet epidemiological data:

59
graft versus host disease
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

OMIM 57 614395
KEGG 37 H00084
ICD10 via Orphanet 34 T86.0
UMLS via Orphanet 73 C0018133
Orphanet 59 ORPHA39812
UMLS 72 C0018133

Summaries for Graft-Versus-Host Disease

OMIM : 57 Transplantation of hematopoietic stem cells is a successful therapy for some tumors derived from bone marrow precursors, such as certain leukemias and lymphomas, and it can be used to cure some primary immunodeficiencies and inherited hematopoietic stem-cell diseases. One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease (GVHD), in which mature donor T cells that contaminate the allogeneic bone marrow recognize the tissues of the recipient as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease. GVHD is particularly virulent when there is a mismatch of a major major histocompatibility complex (MHC) class I or class II antigen. Most transplants are therefore undertaken only when the donor and recipient are HLA-matched sibs or, less frequently, when there is an HLA-matched unrelated donor. However, GVHD also occurs in the context of disparities between minor histocompatibility antigens, and immunosuppression must be used in every stem-cell transplant (summary by Janeway et al., 2005). At the core of the immunogenetic basis for GVHD is the diversity of HLA, killer immunoglobulin-like receptors (KIRs; see 604936), and cytokine genes. HLA class I molecules function as ligands for natural killer cell inhibitory KIRs, indicating that GVHD results from a complex interplay between innate and adaptive immune responses. Cytokines may modulate the intensity of tissue injury and inflammation in GVHD, and therefore cytokine polymorphisms in either patient or donor or both may explain individual risks of GVHD (review by Petersdorf and Malkki, 2006). (614395)

MalaCards based summary : Graft-Versus-Host Disease, also known as graft-versus-host disease, susceptibility to, is related to chronic graft versus host disease and acute graft versus host disease. An important gene associated with Graft-Versus-Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Graft-versus-host disease and Innate Immune System. The drugs Lomustine and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include Bone, bone and bone marrow, and related phenotypes are elevated hepatic transaminase and diarrhea

KEGG : 37
Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.

Wikipedia : 75 Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue... more...

Related Diseases for Graft-Versus-Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Graft-Versus-Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 949)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 35.6 TNF IL1A IL10 IFNG
2 acute graft versus host disease 34.1 TNF IL2 IL10 IFNG GZMB FASLG
3 bronchiolitis obliterans 33.4 TNF IL6 IL10 IFNG GZMB
4 exanthem 32.4 TNF IL6 IL2
5 bronchiolitis 32.1 TNF IL6 IL10 IFNG
6 keratoconjunctivitis 32.0 TNF IL2 IFNG
7 lichen planus 31.8 TNF IFNG GZMB
8 conjunctivitis 31.8 IL6 IL2 IFNG
9 aspergillosis 31.7 TNF IL10 IFNG
10 immune deficiency disease 31.6 IL2 IL1A IL10
11 cutaneous t cell lymphoma 31.5 IL2 IFNG GZMB
12 myasthenia gravis 31.4 TNF IL2 IL10 IFNG
13 lymphoproliferative syndrome 31.4 IL2 FASLG FAS
14 lymphopenia 31.3 IL2 IFNG FASLG FAS
15 post-transplant lymphoproliferative disease 31.3 TNF IL6 IL1A IL10
16 dermatitis, atopic 31.2 TNF IL2 IL10 IFNG
17 hepatitis a 31.2 TNF IL10 IFNG
18 cholangitis 31.1 TNF IL6 HLA-DRB1 HLA-B
19 viral hepatitis 31.0 TNF FASLG FAS
20 drug reaction with eosinophilia and systemic symptoms 31.0 TNF HLA-B
21 lung disease 30.9 TNF IL6 IL1B IL10
22 tetanus 30.9 IL2 IL10 IFNG
23 lichen sclerosus 30.9 HLA-DRB1 HLA-DQB1 GZMB
24 erythema multiforme 30.9 TNF IL2 IFNG GZMB FASLG
25 polyradiculoneuropathy 30.9 IL10 IFNG HLA-DRB1
26 chronic active epstein-barr virus infection 30.9 IL2 IL10 IFNG
27 hand, foot and mouth disease 30.9 IL6 IL10 IFNG
28 skin disease 30.8 TNF IL1A IL10 IFNG HLA-C HLA-B
29 panniculitis 30.8 IFNG GZMB FAS
30 cutaneous leishmaniasis 30.8 TNF IL10 IFNG
31 uveitis 30.8 TNF IL1A IL10 IFNG HLA-B
32 keratoconjunctivitis sicca 30.8 TNF IL6 IL1B IL1A IL10
33 anterior uveitis 30.7 IL6 HLA-B HLA-A
34 hematopoietic stem cell transplantation 30.7 TNF IL6 IL2 IL10 IFNG HLA-C
35 bacterial infectious disease 30.7 TNF IL6 IL1B IL10 IFNG
36 herpes zoster 30.7 IL2 IL10 IFNG HLA-B HLA-A
37 microscopic polyangiitis 30.7 TNF HLA-DRB1
38 acute respiratory distress syndrome 30.7 TNF IL6 IL1B
39 leprosy 3 30.6 TNF IL2 IL10 IFNG
40 gastroenteritis 30.6 TNF IL6 IL1B IL10
41 poliomyelitis 30.6 TNF IL10 IFNG
42 fixed drug eruption 30.5 IL2 IFNG
43 peritonitis 30.5 TNF IL6 IL1B IL10
44 omenn syndrome 30.5 TNF IL10 IFNG
45 t-cell large granular lymphocyte leukemia 30.5 IL2 GZMB FASLG
46 peptic ulcer disease 30.5 TNF IL1B IL10
47 hemophagocytic lymphohistiocytosis 30.4 TNF IL10 IFNG GZMB FAS
48 pneumonia 30.4 TNF IL6 IL1B IL10
49 demyelinating disease 30.4 TNF IL1B IL10 IFNG
50 pericarditis 30.4 TNF IL6 IL1B IFNG

Graphical network of the top 20 diseases related to Graft-Versus-Host Disease:



Diseases related to Graft-Versus-Host Disease

Symptoms & Phenotypes for Graft-Versus-Host Disease

Human phenotypes related to Graft-Versus-Host Disease:

59 32 (show all 41)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated hepatic transaminase 59 32 frequent (33%) Frequent (79-30%) HP:0002910
2 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
3 skin erosion 59 32 frequent (33%) Frequent (79-30%) HP:0200041
4 oral ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0000155
5 maculopapular exanthema 59 32 frequent (33%) Frequent (79-30%) HP:0040186
6 stomatitis 59 32 frequent (33%) Frequent (79-30%) HP:0010280
7 chronic hepatitis 59 32 frequent (33%) Frequent (79-30%) HP:0200123
8 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
9 vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002013
10 skeletal muscle atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0003202
11 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
12 scaling skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0040189
13 irritability 59 32 occasional (7.5%) Occasional (29-5%) HP:0000737
14 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
15 myositis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100614
16 gastrointestinal inflammation 59 32 occasional (7.5%) Occasional (29-5%) HP:0004386
17 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
18 limited elbow movement 59 32 occasional (7.5%) Occasional (29-5%) HP:0002996
19 acute hepatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0200119
20 pneumonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002090
21 inflammatory abnormality of the eye 59 32 occasional (7.5%) Occasional (29-5%) HP:0100533
22 hyperbilirubinemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002904
23 hepatosplenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001433
24 tachycardia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001649
25 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
26 limited shoulder movement 59 32 occasional (7.5%) Occasional (29-5%) HP:0006467
27 fasciitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100537
28 elevated alkaline phosphatase 59 32 occasional (7.5%) Occasional (29-5%) HP:0003155
29 recurrent gastroenteritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0031123
30 hemophagocytosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012156
31 cutaneous sclerotic plaque 59 32 occasional (7.5%) Occasional (29-5%) HP:0031359
32 lichenoid skin lesion 59 32 occasional (7.5%) Occasional (29-5%) HP:0031452
33 failure to thrive 59 32 very rare (1%) Very rare (<4-1%) HP:0001508
34 lipodystrophy 59 32 very rare (1%) Very rare (<4-1%) HP:0009125
35 decreased lacrimation 59 32 very rare (1%) Very rare (<4-1%) HP:0000633
36 trismus 59 32 very rare (1%) Very rare (<4-1%) HP:0000211
37 lymphadenopathy 59 32 very rare (1%) Very rare (<4-1%) HP:0002716
38 dupuytren contracture 59 32 very rare (1%) Very rare (<4-1%) HP:0005679
39 stiff interphalangeal joints 59 32 very rare (1%) Very rare (<4-1%) HP:0005198
40 recurrent infections 59 Frequent (79-30%)
41 inflammatory abnormality of the skin 59 Very frequent (99-80%)

Clinical features from OMIM:

614395

GenomeRNAi Phenotypes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.89 CD28 FAS GZMB HLA-DQB1 IL10 IL1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.89 CD28 FAS GZMB HLA-DQB1 IL10 IL1A

MGI Mouse Phenotypes related to Graft-Versus-Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 CENPF FAS FASLG HLA-DQB1 IFNG IL10
2 hematopoietic system MP:0005397 10.14 CD28 FAS FASLG HLA-DQB1 IFNG IL10
3 digestive/alimentary MP:0005381 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
4 immune system MP:0005387 10.11 CD28 FAS FASLG HLA-DQB1 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.09 CD28 FAS FASLG HLA-DQB1 IFNG IL10
6 integument MP:0010771 9.97 CD28 FAS FASLG IFNG IL10 IL1A
7 liver/biliary system MP:0005370 9.86 FAS FASLG HLA-DQB1 IFNG IL10 IL2
8 neoplasm MP:0002006 9.85 CD28 FAS FASLG IFNG IL10 IL1A
9 respiratory system MP:0005388 9.56 FAS FASLG HLA-DQB1 IFNG IL10 IL2
10 vision/eye MP:0005391 9.23 CD28 FAS FASLG IFNG IL10 IL2

Drugs & Therapeutics for Graft-Versus-Host Disease

Drugs for Graft-Versus-Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 470)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Histamine Approved, Investigational Phase 4 51-45-6 774
6
Simethicone Approved Phase 4 8050-81-5
7
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
10
Povidone Approved Phase 4 9003-39-8
11
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
14
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
15
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
16
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
17
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
18
Treosulfan Investigational Phase 4 299-75-2 9296
19 Olive Phase 4
20 Chlorhexidine gluconate Phase 4
21 Neurotransmitter Agents Phase 4
22 Anesthetics Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25 Central Nervous System Depressants Phase 4
26 Anti-Allergic Agents Phase 4
27 Anesthetics, Local Phase 4
28 Histamine H1 Antagonists Phase 4
29
Histamine Phosphate Phase 4 51-74-1 65513
30 Histamine Antagonists Phase 4
31 Hypnotics and Sedatives Phase 4
32 Antipruritics Phase 4
33 Antacids Phase 4
34 Anti-Ulcer Agents Phase 4
35 Sodium Channel Blockers Phase 4
36 Diuretics, Potassium Sparing Phase 4
37 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
38 Plasma Substitutes Phase 4
39 Anti-Arrhythmia Agents Phase 4
40 Viscosupplements Phase 4
41 Emollients Phase 4
42 Blood Substitutes Phase 4
43 Micronutrients Phase 4
44 Trace Elements Phase 4
45 Nutrients Phase 4
46 Vitamin D2 Phase 4
47 Ergocalciferols Phase 4
48 Hydroxycholecalciferols Phase 4
49 glucocorticoids Phase 4
50 Hormones Phase 4

Interventional clinical trials:

(show top 50) (show all 1719)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
6 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
7 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
8 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
10 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
11 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
12 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
13 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
14 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
15 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
16 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
17 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
18 Ruxolitinib in Combination With Corticosteroid as First Line Therapy for the Treatment of High Risk Acute Graft-Versus-Host Disease Recruiting NCT04061876 Phase 4 Ruxolitinib;Corticosteroid
19 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
20 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
21 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Recruiting NCT01856803 Phase 4 anti thymoglobulin
22 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
23 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
24 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
25 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
26 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
27 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
28 Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients Not yet recruiting NCT03963999 Phase 4 Contrast Enhanced Ultrasound (CEUS)
29 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
30 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
31 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
32 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
33 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
34 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
35 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
36 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
37 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
38 Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant Unknown status NCT02240992 Phase 2, Phase 3
39 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
40 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
41 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
42 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
43 Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR) Unknown status NCT00342316 Phase 3
44 Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
45 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
46 Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
47 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
48 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
49 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
50 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate

Search NIH Clinical Center for Graft-Versus-Host Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alemtuzumab
Antilymphocyte immunoglobulin (horse)
Ciclosporin
Daclizumab
Etanercept
Methotrexate
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Sirolimus
Tacrolimus
Tacrolimus
Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Graft-Versus-Host Disease cell therapies at LifeMap Discovery.

Genetic Tests for Graft-Versus-Host Disease

Genetic tests related to Graft-Versus-Host Disease:

# Genetic test Affiliating Genes
1 Graft-Versus-Host Disease, Susceptibility to 29 IL10

Anatomical Context for Graft-Versus-Host Disease

MalaCards organs/tissues related to Graft-Versus-Host Disease:

41
Bone, Bone Marrow, T Cells, Myeloid, Liver, Skin, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Graft-Versus-Host Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Graft-Versus-Host Disease

Articles related to Graft-Versus-Host Disease:

(show top 50) (show all 20826)
# Title Authors PMID Year
1
Genetics of risk factors for graft-versus-host disease. 9 38 8
16412785 2006
2
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. 9 38 8
14657427 2003
3
A protective gene for graft-versus-host disease. 38 8
14657422 2003
4
Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. 8
9162098 1997
5
Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. 9 38
19965675 2010
6
Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. 9 38
20025985 2010
7
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. 9 38
20160060 2010
8
CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. 9 38
20053336 2010
9
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. 9 38
19789388 2010
10
Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation. 9 38
19462221 2009
11
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. 9 38
19409109 2009
12
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. 9 38
19159415 2009
13
Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. 9 38
19221040 2009
14
Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. 9 38
19260829 2009
15
Donor treatment with a multipegylated G-CSF maximizes graft-versus-leukemia effects. 9 38
19135951 2009
16
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. 9 38
18614760 2008
17
Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. 9 38
18541194 2008
18
Extracorporeal photopheresis affects co-stimulatory molecule expression and interleukin-10 production by dendritic cells in graft-versus-host disease patients. 9 38
18234053 2008
19
Interleukin-10 gene polymorphism in bone marrow transplant recipients. 9 38
18405249 2008
20
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. 9 38
18301339 2008
21
[Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. 9 38
18681305 2008
22
Importance of interleukin-7 in the development of experimental graft-versus-host disease. 9 38
18158957 2008
23
IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. 9 38
18021367 2007
24
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. 9 38
17889355 2007
25
Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. 9 38
17984846 2007
26
Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. 9 38
17429441 2007
27
Granulocyte colony-stimulating factor for the induction of T-cell tolerance. 9 38
17632408 2007
28
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. 9 38
17496542 2007
29
Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. 9 38
17331846 2007
30
Expression of CCR5 in graft-versus-host disease (GVHD) of the skin: immunohistochemical staining of 38 cases. 9 38
17352723 2007
31
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. 9 38
16937391 2007
32
Interleukin-18 and the pathogenesis of inflammatory diseases. 9 38
17336692 2007
33
CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 9 38
17145599 2006
34
Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. 9 38
16984283 2006
35
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. 9 38
16864058 2006
36
Effect of interleukin-15 on alloreactivity in umbilical cord blood. 9 38
16860714 2006
37
DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. 9 38
16707472 2006
38
No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. 9 38
16646673 2006
39
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. 9 38
16123384 2006
40
Daclizumab for children with corticosteroid refractory graft-versus-host disease. 9 38
16247417 2006
41
Genomic polymorphism and allogeneic hematopoietic transplantation outcome. 9 38
16399580 2006
42
Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis. 9 38
16367941 2006
43
Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation. 9 38
16344675 2005
44
Cytokine-mediated signalling and early defects in lymphoid development. 9 38
16264332 2005
45
Interleukin-18 treatment options for inflammatory diseases. 9 38
20477603 2005
46
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. 9 38
16219576 2005
47
IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. 9 38
15976176 2005
48
Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. 9 38
16125641 2005
49
Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution. 9 38
15778730 2005
50
IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. 9 38
15814693 2005

Variations for Graft-Versus-Host Disease

Copy number variations for Graft-Versus-Host Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 188553 4 66300000 70400000 Absence of gene UGT2B17 Graft versus host disease

Expression for Graft-Versus-Host Disease

Search GEO for disease gene expression data for Graft-Versus-Host Disease.

Pathways for Graft-Versus-Host Disease

Pathways related to Graft-Versus-Host Disease according to KEGG:

37
# Name Kegg Source Accession
1 Graft-versus-host disease hsa05332

Pathways related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 TNF IL6 IL2 IL1B IL1A IL10
2
Show member pathways
13.77 TNF IL6 IL2 IL1B IL1A IL10
3
Show member pathways
13.52 TNF IL6 IL2 IL1B IL1A IL10
4
Show member pathways
13.42 TNF IL6 IL2 IL1B IL1A IL10
5
Show member pathways
13.36 TNF IL6 IL2 IL1B IL1A IL10
6
Show member pathways
13.29 TNF IL2 IL1B IL1A IFNG HLA-DRB1
7
Show member pathways
13.23 TNF IL6 IL2 IL1B IL10 IFNG
8
Show member pathways
13.12 TNF IL6 IL2 HLA-C HLA-B HLA-A
9
Show member pathways
13.09 TNF IL6 IL1B HLA-C HLA-B HLA-A
10 12.89 IL6 IL2 IFNG FASLG FAS
11 12.83 TNF IL1B IL1A FASLG FAS
12
Show member pathways
12.8 TNF IL1B IL1A IFNG FASLG FAS
13
Show member pathways
12.8 TNF IL2 IL10 IFNG HLA-DRB1 HLA-DQB1
14
Show member pathways
12.78 TNF IL6 IL2 IL1B IL1A
15
Show member pathways
12.72 TNF IL6 IL2 IL1B IL10 IFNG
16
Show member pathways
12.7 IFNG HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B
17 12.7 TNF IL2 IL1B IL10 IFNG GZMB
18
Show member pathways
12.69 TNF IL1B IL1A FASLG FAS
19
Show member pathways
12.67 TNF IL6 IL2 IL1B IL1A IL10
20
Show member pathways
12.62 TNF IL2 IFNG HLA-C HLA-B HLA-A
21
Show member pathways
12.53 TNF IL6 IL2 IL1B IL1A IL10
22
Show member pathways
12.45 IL2 HLA-DRB1 HLA-DQB1 CD28
23
Show member pathways
12.45 TNF IL6 IL2 IL1B IFNG
24 12.45 TNF IL6 IL2 HLA-DRB1 HLA-DQB1 HLA-DPB1
25
Show member pathways
12.43 TNF IL6 IL1B IL1A IFNG
26
Show member pathways
12.4 TNF IL6 IL1B IFNG
27
Show member pathways
12.4 TNF IL1B IL1A IL10 IFNG HLA-DRB1
28
Show member pathways
12.39 TNF IL1A GZMB FASLG FAS
29
Show member pathways
12.39 TNF IL1B IL1A IFNG FASLG FAS
30
Show member pathways
12.36 TNF IL6 IL1B IFNG FASLG FAS
31
Show member pathways
12.35 TNF IL6 IL2 IL1B IL10
32
Show member pathways
12.34 TNF IL6 IL2 IL1B IL1A IL10
33 12.33 TNF GZMB FASLG FAS
34 12.32 TNF IL6 IL1B IL1A IL10
35 12.32 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
36 12.31 IL6 IL1A HLA-C HLA-B HLA-A
37 12.31 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
38
Show member pathways
12.3 TNF IL6 IL1B IL1A
39
Show member pathways
12.29 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD28
40
Show member pathways
12.29 TNF IL6 IL2 IL1B IL1A IL10
41 12.27 TNF IL6 IL1B IL1A IL10 IFNG
42
Show member pathways
12.23 TNF IL6 IL2 IL1B IL10 IFNG
43
Show member pathways
12.21 IL6 IL2 IL1B IL1A IL10 IFNG
44 12.21 TNF IL6 IL2 IL1B IL1A IFNG
45 12.19 TNF IL1B IL1A IFNG
46 12.19 TNF IL6 IL2 IL10 IFNG CD28
47 12.18 TNF IL6 IL1B IL1A IL10 FASLG
48 12.15 TNF IL1B IL1A IFNG
49
Show member pathways
12.15 TNF IL6 IL1B IFNG
50
Show member pathways
12.15 IL2 IL1B IFNG HLA-DRB1 HLA-A GZMB

GO Terms for Graft-Versus-Host Disease

Cellular components related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.91 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
2 cell surface GO:0009986 9.81 TNF HLA-DRB1 HLA-DPB1 HLA-C HLA-B HLA-A
3 trans-Golgi network membrane GO:0032588 9.71 HLA-DRB1 HLA-DQB1 HLA-DPB1
4 recycling endosome membrane GO:0055038 9.7 HLA-C HLA-B HLA-A
5 phagocytic vesicle membrane GO:0030670 9.67 HLA-C HLA-B HLA-A
6 endocytic vesicle membrane GO:0030666 9.65 HLA-DRB1 HLA-DQB1 HLA-DPB1
7 transport vesicle membrane GO:0030658 9.63 HLA-DRB1 HLA-DQB1 HLA-DPB1
8 clathrin-coated endocytic vesicle membrane GO:0030669 9.58 HLA-DRB1 HLA-DQB1 HLA-DPB1
9 MHC class II protein complex GO:0042613 9.5 HLA-DRB1 HLA-DQB1 HLA-DPB1
10 MHC class I protein complex GO:0042612 9.43 HLA-C HLA-B HLA-A
11 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
12 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
13 extracellular space GO:0005615 10.11 TNF IL6 IL2 IL1B IL1A IL10
14 extracellular region GO:0005576 10.07 TNF IL6 IL2 IL1B IL1A IL10

Biological processes related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.99 TNF IL6 IL1B IL10
2 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL2 IL1B IFNG FAS
3 T cell receptor signaling pathway GO:0050852 9.96 HLA-DRB1 HLA-DQB1 HLA-DPB1 CD28
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL1B IL10
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.91 HLA-DRB1 HLA-DQB1 HLA-DPB1
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.9 TNF FASLG FAS
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 IL6 IL2 IFNG
8 regulation of insulin secretion GO:0050796 9.9 TNF IL1B IFNG
9 type I interferon signaling pathway GO:0060337 9.89 HLA-C HLA-B HLA-A
10 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
11 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IL6 IL2 IL1B IL1A IL10
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF IL1B IFNG
13 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.85 TNF IL1B IL1A
14 apoptotic signaling pathway GO:0097190 9.85 TNF FASLG FAS CD28
15 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.83 IL2 IL1B IL1A
16 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.83 HLA-C HLA-B HLA-A
17 humoral immune response GO:0006959 9.83 TNF IL6 IFNG CD28
18 positive regulation of cytokine secretion GO:0050715 9.82 TNF IL1A IL10
19 positive regulation of mitotic nuclear division GO:0045840 9.81 IL1B IL1A CD28
20 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.8 HLA-C HLA-B HLA-A
21 negative regulation of neurogenesis GO:0050768 9.8 TNF IL6 IL1B
22 positive regulation of interferon-gamma production GO:0032729 9.8 TNF IL2 IL1B HLA-DPB1
23 positive regulation of T cell mediated cytotoxicity GO:0001916 9.79 HLA-C HLA-B HLA-A
24 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
25 extrinsic apoptotic signaling pathway GO:0097191 9.78 TNF IFNG FASLG FAS
26 regulation of regulatory T cell differentiation GO:0045589 9.77 IL2 IFNG CD28
27 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 TNF IL1B IFNG
28 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
29 response to glucocorticoid GO:0051384 9.74 TNF IL6 IL10
30 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL6 IL2
31 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL2 CD28
32 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.73 HLA-DRB1 HLA-DQB1 HLA-DPB1
33 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
34 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B
35 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
36 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B
37 ectopic germ cell programmed cell death GO:0035234 9.71 IL1B IL1A
38 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.71 IL1B IL1A CD28
39 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 TNF IL10
40 protection from natural killer cell mediated cytotoxicity GO:0042270 9.7 HLA-B HLA-A
41 positive regulation of fever generation GO:0031622 9.69 TNF IL1B
42 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.69 HLA-DRB1 HLA-DQB1
43 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.69 HLA-C HLA-B HLA-A
44 sequestering of triglyceride GO:0030730 9.68 TNF IL1B
45 receptor biosynthetic process GO:0032800 9.67 TNF IL10
46 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.67 HLA-DRB1 HLA-DQB1
47 fever generation GO:0001660 9.66 IL1B IL1A
48 positive regulation of T cell proliferation GO:0042102 9.65 IL6 IL2 IL1B HLA-DPB1 CD28
49 positive regulation of vitamin D biosynthetic process GO:0060557 9.63 TNF IFNG
50 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.63 HLA-C HLA-B HLA-A

Molecular functions related to Graft-Versus-Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL6 IL2 IL1B IL1A IL10
2 interleukin-1 receptor binding GO:0005149 9.32 IL1B IL1A
3 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
4 peptide antigen binding GO:0042605 9.1 HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-C HLA-B HLA-A
5 protein binding GO:0005515 10.16 TNF IL6 IL2 IL1B IL1A IL10

Sources for Graft-Versus-Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....